Регистрация | Вход в службу | FAQ      [?] 

Cancer Chemotherapy and Pharmacology

Статьи последних нескольких выпусков журнала Cancer Chemotherapy and Pharmacology © Springer
  • A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 1-9.
    by Park, Se, Nam, Eunmi, Bang, Soo-Mee, Cho, Eun, Shin, Dong, Lee, Jae
  • Sequential vinorelbinecapecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 11-18.
    by Ghosn, Marwan, Kattan, Joseph, Farhat, Fadi, Younes, Fariha, Nasr, Fadi, Moukadem, Walid, Gasmi, Jamal, Chahine, Georges
  • Preclinical studies of treosulfan demonstrate potent activity in Ewings sarcoma
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 19-31.
    by Werner, Sebastian, Mendoza, Arnulfo, Hilger, Ralf, Erlacher, Miriam, Reichardt, Wilfried, Lissat, Andrej, Konanz, Claudia, Uhl, Marcus, Niemeyer, Charlotte, Khanna, Chand, Kontny, Udo
  • Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 33-41.
    by Logan, Richard, Gibson, Rachel, Bowen, Joanne, Stringer, Andrea, Sonis, Stephen, Keefe, Dorothy
  • Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 43-49.
    by Tomonaga, Nanae, Nakamura, Yoichi, Soda, Hiroshi, Nagashima, Seiji, Nakano, Hirofumi, Kinoshita, Akitoshi, Fukuda, Masaaki, Fukuda, Minoru, Takatani, Hiroshi, Soejima, Yoshifumi, Oka, Mikio, Kohno, Shigeru
  • In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 51-58.
    by Smith, Judith, Gaikwad, Anjali, Yu, Jiang, Wolf, Judith, Brown, Jubilee, Ramondetta, Lois, Stewart, Clinton
  • A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma EpsteinBarr virus DNA as a biomarker of efficacy
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 59-64.
    by Ma, Brigette, Hui, Edwin, King, Ann, To, , Mo, Frankie, Leung, Sing, Kam, Michael, Lo, , Zee, Benny, Mok, Tony, Ahuja, Anil, Chan, Anthony
  • Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 65-75.
    by Cole, Peter, Drachtman, Richard, Masterson, Margaret, Smith, Angela, Glod, John, Zebala, John, Lisi, Stacey, Drapala, Drew-Anne, Kamen, Barton
  • A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 77-84.
    by Lee, Jeeyun, Im, Young-Hyuck, Cho, Eun, Hong, Yong, Lee, Hyo, Kim, Hyo, Kim, Mi-Jin, Kim, Kwhanmien, Kang, Won, Park, Keunchil, Shim, Young
  • Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 85-96.
    by Guarcello, Vincenzo, Blanquicett, Carmelo, Naguib, Fardos, El Kouni, Mahmoud
  • Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 97-109.
    by Guo, Feng, Letrent, Stephen, Munster, Pamela, Britten, Carolyn, Gelmon, Karen, Tolcher, Anthony, Sharma, Amarnath
  • Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 111-116.
    by Kubo, Tadahiko, Shimose, Shoji, Matsuo, Toshihiro, Sakai, Akira, Ochi, Mitsuo
  • Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 117-122.
    by Wang, Wei, Xia, Cindy, Liu, Ning, Gan, Liang-Shang, Zheng, Jiang
  • Pharmacodynamic model for chemotherapy-induced anemia in rats
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 123-133.
    by Woo, Sukyung, Krzyzanski, Wojciech, Jusko, William
  • Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 135-147.
    by Fetterly, Gerald, Owen, Joel, Stuyckens, Kim, Passarell, Julie, Zannikos, Peter, Soto-Matos, Arturo, Izquierdo, Miguel, Perez-Ruixo, Juan
  • Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 149-157.
    by Bailey, Howard, Attia, Steven, Love, Richard, Fass, Terri, Chappell, Rick, Tutsch, Kendra, Harris, Linda, Jumonville, Alcee, Hansen, Richard, Shapiro, Gary, Stewart, James
  • Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 159-164.
    by Osako, Tomo, Ito, Yoshinori, Takahashi, Shunji, Tokudome, Nahomi, Iwase, Takuji, Hatake, Kiyohiko
  • Bisphosphonates induce apoptosis in CLL cells independently of MDR phenotype
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 165-171.
    by Silva, Karina, Vasconcellos, Deborah, Castro, Eric, Vasconcelos, Flavia Da, Bigni, Ricardo, Maia, Raquel
  • Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 173-180.
    by Horti, , Juhasz, , Monostori, , Maeda, , Eckhardt, , Bodrogi,
  • Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome
    Cancer Chemotherapy and Pharmacology, Vol. 62, No. 1. (June 2008), pp. 181-182.
    by Chim,
  • Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
    Cancer chemotherapy and pharmacology, Vol. 61, No. 6. (May 2008), pp. 903-909.
    by Vincent Launay-Vacher, Jean-Baptiste B Rey, Corinne Isnard-Bagnis, Gilbert Deray, Mikael Daouphars
    posted by 2 people vlv75 jyuh
  • Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 911-921.
    by Gourdeau, Henriette, Mcalpine, James, Ranger, Maxime, Simard, Bryan, Berger, Francois, Beaudry, Francis, Falardeau, Pierre
  • IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 923-932.
    by Patterson, Jon, Palombella, Vito, Fritz, Christian, Normant, Emmanuel
  • Augmented antioxidant status in Tamoxifen treated postmenopausal women with breast cancer on co-administration with Coenzyme Q10, Niacin and Riboflavin
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 933-941.
    by Yuvaraj, Srinivasan, Premkumar, Vummidi, Vijayasarathy, Kothandaraman, Gangadaran, Sitthu, Sachdanandam, Panchanatham
  • Suppression of Bcl-xL expression by a novel tumor-specific RNA interference system inhibits proliferation and enhances radiosensitivity in prostatic carcinoma cells
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 943-952.
    by Wang, Rui, Lin, Fang, Wang, Xi, Gao, Ping, Dong, Ke, Wei, San-Hua, Cheng, Shi-Yin, Zhang, Hui-Zhong
  • A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 953-963.
    by Meng, Fanying, Cai, Xiaohong, Duan, Jianxin, Matteucci, Mark, Hart, Charles
  • Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 965-971.
    by Rocca, Andrea, Viale, Giuseppe, Gelber, Richard, Bottiglieri, Luca, Gelber, Shari, Pruneri, Giancarlo, Ghisini, Raffaella, Balduzzi, Alessandra, Pietri, Elisabetta, Dalessandro, Claudia, Goldhirsch, Aron, Colleoni, Marco
  • New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 973-978.
    by Kawano, Hirokazu, Komaba, Shintaro, Yamasaki, Tsugiko, Maeda, Mitsuyo, Kimura, Yoshimitsu, Maeda, Akito, Kaneda, Yasufumi
  • Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 979-987.
    by Chen, Jianli, Adikari, Mahesha, Pallai, Rajash, Parekh, Hemant, Simpkins, Henry
  • Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 989-995.
    by Masuda, Norikazu, Taguchi, Tetsuya, Nakayama, Takahiro, Shiba, Eiichi, Watatani, Masahiro, Kurebayashi, Junichi, Takatsuka, Yuichi, Sakamoto, Junichi, Noguchi, Shinzaburo
  • The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 997-1005.
    by Lu, Jianjun, Jackson, John, Gleave, Martin, Burt, Helen
  • Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1007-1018.
    by Serafim, Teresa, Oliveira, Paulo, Sardao, Vilma, Perkins, Ed, Parke, Donna, Holy, Jon
  • A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1019-1026.
    by Chiorean, , Dragovich, Tomislav, Hamm, John, Langmuir, Virginia, Kroll, Stewart, Jung, Donald, Colowick, Alan, Tidmarsh, George, Loehrer, Patrick
  • Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 l) blood samples
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1027-1035.
    by Boghaert, Erwin, Khandke, Kiran, Sridharan, Latha, Dougher, Maureen, Dijoseph, John, Kunz, Arthur, Hamann, Philip, Moran, Justin, Chaudhary, Inder, Damle, Nitin
  • Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1037-1044.
    by Song, Pengfei, Ma, Fei, Wang, Fan, Wang, Xiangdi, Patil, Renukadevi, Ramagiri, Suma, Orr, William, Miller, Duane, Geisert, Eldon, Yates, Charles
  • Disruption of Golgi processing by 2-phenyl benzimidazole analogs blocks cell proliferation and slows tumor growth
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1045-1058.
    by Lio, Shirley, Johnson, Jessica, Chatterjee, Arka, Ludwig, Jeffrey, Millis, Diane, Banie, Homayon, Sircar, Jagadish, Sinha, Anjana, Richards, Mark
  • Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1059-1067.
    by Prados, Michael, Yung, , Wen, Patrick, Junck, Larry, Cloughesy, Timothy, Fink, Karen, Chang, Susan, Robins, , Dancey, Janet, Kuhn, John
  • A phase I clinical trial of low-dose interferon--2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1069-1073.
    by Amato, Robert, Khan, Muhammad
  • Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1075-1081.
    by Hoebers, , Pluim, , Hart, , Verheij, , Balm, , Fons, , Rasch, , Schellens, , Stalpers, , Bartelink, , Begg,
  • Dermatitis after suspected imatiniblevothyroxine interaction in a patient with gastrointestinal stromal tumor
    Cancer Chemotherapy and Pharmacology, Vol. 61, No. 6. (May 2008), pp. 1083-1084.
    by Cholongitas, Evangelos, Pipili, Chrysoula, Katsogridakis, Konstadinos, Relos, Konstadinos, Dasenaki, Maria
  • Tumor specific cytotoxicity of glucosylceramide
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 767-775.
    by Oku, Hirosuke, Wongtangtintharn, Sawitree, Iwasaki, Hironori, Inafuku, Masashi, Shimatani, Masayuki, Toda, Takayoshi
  • Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14C-bortezomib
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 777-787.
    by Hemeryck, Alex, Geerts, Rita, Monbaliu, Johan, Hassler, Stephan, Verhaeghe, Tom, Diels, Luc, Verluyten, Willy, Beijsterveldt, Ludy, Mamidi, Rao, Janssen, Cor, Coster, Roland
  • Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structureactivity relationship
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 789-797.
    by Katayama, Kazuhiro, Masuyama, Kazuto, Yoshioka, Sho, Hasegawa, Hitomi, Mitsuhashi, Junko, Sugimoto, Yoshikazu
  • Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 799-809.
    by Guo, Feng, Letrent, Stephen, Sharma, Amarnath
  • Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 811-819.
    by Yong, Wei, Desai, Apurva, Innocenti, Federico, Ramirez, Jacqueline, Shepard, Dale, Kobayashi, Ken, House, Larry, Fleming, Gini, Vogelzang, Nicholas, Schilsky, Richard, Ratain, Mark
  • Assessing the therapeutic and toxicological effects of cesium chloride following administration to nude mice bearing PC-3 or LNCaP prostate cancer xenografts
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 821-829.
    by Low, Jonathan, Wasan, Kishor, Fazli, Ladan, Eberding, Andy, Adomat, Hans, Guns, Emma
  • Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 831-839.
    by Aneja, Ritu, Dhiman, Neerupma, Idnani, Jyoti, Awasthi, Anshumali, Arora, Sudershan, Chandra, Ramesh, Joshi, Harish
  • Effect of the Cdk-inhibitor roscovitine on mouse hematopoietic progenitors in vivo and in vitro
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 841-849.
    by Song, Hairong, Vita, Marina, Sallam, Hatem, Tehranchi, Ramin, Nilsson, Christina, Siden, Ake, Hassan, Zuzana
  • Validation of the comet-X assay as a pharmacodynamic assay for measuring DNA cross-linking produced by the novel anticancer agent RH1 during a phase I clinical trial
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 851-861.
    by Danson, , Ranson, , Denneny, , Cummings, , Ward,
  • Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
    Cancer Chemotherapy and Pharmacology, Vol. 60, No. 6. (November 2007), pp. 863-869.
    by Kim, Jong, Sohn, Sang, Song, Hong, Kwon, Ki-Young, Do, Young, Lee, Kyung, Hyun, Myung, Ryoo, Hun, Bae, Sung, Park, Keon, Baek, Jin, Lee, Won, Chung, Joo, Cho, Goon, Sohn, Chang-Hak, Jang, Jung, Chung, Ho, Yu, Wansik
    • Вы можете ссылаться на эту страницу по адресу: http://www.citeulike.org/journal/klu-280

    Result page: 1 2 3 4 5 Next RIS BibTeX RSS
    CiteULike organises scholarly (or academic) papers or literature and provides bibliographic (which means it makes bibliographies) for universities and higher education establishments. It helps undergraduates and postgraduates. People studying for PhDs or in postdoctoral (postdoc) positions. The service is similar in scope to EndNote or RefWorks or any other reference manager like BibTeX, but it is a social bookmarking service for scientists and humanities researchers.